Most patients who explore clinical trials and don't end up enrolling weren't rejected — they dropped out during the process. The screening visit was further away than expected. The visit schedule turned out to be incompatible with work. The informed consent document was 40 pages and nobody walked them through it. A medication they take daily turned out to be on the protocol's prohibited list. None of these are insurmountable obstacles — but none of them are explained in trial listings, either. This guide covers what the enrollment process actually involves at each step, so you can evaluate whether a specific trial is genuinely feasible before you commit time, travel, and expectation to it.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Enrolling in a clinical trial involves six steps: finding a relevant study, reviewing eligibility criteria before you call, making initial contact with the research team, attending a formal screening visit, signing informed consent, and completing the protocol. Each step has practical realities — timelines, failure rates, logistical demands — that trial listings never surface. The 30–50% screening failure rate isn't a reflection of patient quality; it's a normal feature of how trials operate. Understanding the full process upfront prevents the unexpected withdrawal that research sites see most often, and that leaves everyone's time wasted.
- The screen failure rate — 30–50% of patients who attend screening visits — is structural, not personal. The most common reasons are lab values outside the protocol window and concomitant medication conflicts. Both are knowable before you drive to the site. Ask the coordinator to tell you the three most common screen failure reasons for this specific trial before you make the trip. Many will. The ones who won't are running a screening process that wastes your time.
- Most patients who withdraw mid-trial do so in the first three months, during the highest-burden period. Sponsors design the densest visit schedules into the early treatment phase when PK data is needed and the DLT observation window is running. Ask for the visit-by-visit schedule for the first six months before you consent — the summary table in the consent form often averages across a non-uniform burden that front-loads dramatically.
- Decentralized trial elements are available but not automatic — you have to ask. Over 40% of industry-sponsored trials in 2025 had at least some DCT components: home nursing visits, eConsent, remote monitoring, direct-to-patient drug shipping. Many don't advertise these because they're not available at all sites. If geographic distance is a barrier, ask specifically: "Do any of your participating sites offer home visits or remote visits for any protocol procedures?" The answer may change what's feasible for you.
Step 1: Find a Trial Worth Your Time
ClinicalTrials.gov, maintained by the NIH's National Library of Medicine, is the authoritative registry. Every interventional trial conducted in the US must register there. Filter for "Recruiting" unless you're deliberately exploring what's coming in the pipeline — "Active, not recruiting" trials are still collecting data but won't take new patients. "Not yet recruiting" trials are worth tracking; some open within weeks of that status appearing.
A few things the interface doesn't make obvious: trial listings are often updated months after protocol amendments, so the posted eligibility criteria may be outdated. Contact information usually points to the lead site, not all sites — a trial listed at one institution may have active sites in a dozen other states. And the listed "estimated enrollment" is a target, not a current count; many trials are further along than they appear.
ClinicalMetric aggregates the same ClinicalTrials.gov database with condition-based filtering and plain-language summaries of what each trial is actually testing. ResearchMatch.org (run by Vanderbilt) matches volunteers to researchers based on health profile — useful when you're not sure what disease category to search under. Your condition's patient advocacy organization almost certainly maintains a curated trial finder that surfaces studies the standard search misses or deprioritizes.
One practical search tip: cast broadly on condition terminology. "Multiple sclerosis," "MS," "relapsing-remitting MS," and "RRMS" may each yield different results depending on how a sponsor chose to register. Same disease, different preferred terms. Try all of them.
Step 2: Read the Eligibility Criteria Before You Call
This is where most people spend the least time, and it's where the most time can be saved. Eligibility criteria consist of inclusion criteria (what you must have) and exclusion criteria (what disqualifies you). Read both lists in full. The exclusion criteria are almost always longer, less prominently formatted, and contain most of the surprises.
Some criteria look absolute in the listed text but are defined more specifically in the protocol. "No prior immunotherapy" might mean "no prior checkpoint inhibitors" but allow prior CAR-T or IVIG. "Adequate liver function" means specific enzyme values on a recent blood draw, not a clinician's general judgment. The research coordinator can clarify any ambiguous language — that's exactly what the pre-screening call is designed for. If a single exclusion criterion definitively disqualifies you, save the time and move on. If you're genuinely uncertain about how it applies, call anyway.
Step 3: The First Contact — What to Prepare
Contact information appears on the trial listing — usually a research coordinator or study nurse, sometimes the principal investigator. Email works well for initial contact because it gives you time to present your situation clearly and gives the coordinator time to review it before responding. Phone is better if the trial is actively competing for enrollment slots and close to its target number.
Prepare before you reach out: your diagnosis and molecular subtype (with documentation if you have it), current medications with doses, recent relevant lab results (within 30 days is ideal), and your general geographic location. The coordinator will run a brief informal pre-screen — typically 15–30 minutes — to determine whether you plausibly meet the key criteria. This is assessment, not commitment. You're not signing anything. You can walk away at any point.
If the coordinator tells you you don't appear to qualify, ask two direct questions: Is there another trial at this site that might fit my situation? And do you know of other sites running similar protocols with different criteria? Good coordinators often know the competitive landscape and will point you in a productive direction even when they can't enroll you themselves.
Step 4: The Formal Screening Visit
If you clear the phone pre-screen, you'll be invited to a formal screening visit at the research site. This is the most intensive part of the pre-enrollment process — expect half a day to a full day. The specific assessments depend on the trial, but most involve some combination of:
- Physical examination and structured medical history review
- Blood draws — often multiple tubes covering CBC, comprehensive metabolic panel, and disease-specific biomarkers
- Urine collection and analysis
- 12-lead ECG
- Condition-specific assessments: imaging (CT, MRI, PET, ultrasound), cognitive or functional testing, biopsy in some oncology trials
- Review of medical records from your treating physicians — coordinate this in advance to avoid delays
Between 30–50% of patients who attend screening visits don't ultimately enroll. This isn't a personal failure — it's a normal feature of how protocol-driven research works. A lab value falls outside the required window. An imaging finding triggers an exclusion criterion. A medication interaction wasn't apparent from the pre-screen. The biomarker data, imaging, and lab results generated during a failed screen often have real clinical value. You may learn something meaningful about your condition outside the context of trial enrollment.
Step 5: Informed Consent — Don't Treat This as a Formality
Before any study procedures begin, you must sign an Informed Consent Form (ICF). Phase 3 trial ICFs typically run 20–40 pages. They're legally required to explain: the study's purpose, what procedures you'll undergo, all known and potential risks, possible benefits (including absence of guaranteed personal benefit), your rights as a participant, what happens to your biological samples, confidentiality protections, and compensation arrangements.
Take the document home. Read it with family. Write down questions and bring them to a follow-up call with the coordinator. Your treating physician outside the trial should know you're considering participation and can review the document with you. None of this delays your enrollment in any meaningful way — trial teams expect this process to take days, and they respect patients who engage with it seriously.
Two things are unambiguous and worth stating plainly: signing the ICF is not a binding commitment to complete the trial. Withdrawing at any point — for any reason — has no effect whatsoever on your access to standard medical care. These aren't formalities. They're legal protections that apply unconditionally.
Step 6: Active Participation — the Actual Time Commitment
Visit schedules vary enormously. Some Phase 1 trials require weekly clinic attendance during the dosing period. Some Phase 3 observational studies require one visit every six months. The number to establish before enrolling is total visit burden over the full study duration — not just the first few months, which trials often design to be manageable and then accelerate.
During active participation, you're expected to: attend all scheduled visits, report new symptoms or health changes to the study team promptly (safety monitoring depends on accurate real-time data), provide complete information about any medications or supplements you start or stop, and complete protocol-required questionnaires accurately. Keep a running list of everything you take — prescription drugs, OTC medications, vitamins, herbals. A few of these have meaningful interactions with investigational agents, and the protocol usually specifies prohibited concomitant medications explicitly. Your coordinator reviews this list at enrollment and throughout the study.
Your Rights as a Participant — the Non-Negotiables
- You can withdraw from any trial at any time, for any reason, without penalty or effect on your medical care
- You have the right to receive any new safety information that emerges during the trial that could affect your decision to continue
- Your identity is protected in all published results — de-identification is a regulatory requirement, not an option the sponsor can override
- You are entitled to care for any injury or illness that results directly from study participation — the sponsor bears this financial responsibility
- You have the right to ask any question about the study at any time, and the team is obligated to answer